Biological E Plans the Production of 100 Million Doses per Month of Corbevax

Biological E Limited, is planning to take the production of its vaccine, Corbevax to 100 million doses per month from February 2022. Corbevax is the first indigenously developed protein sub-unit vaccine for covid-19. 

The company, Biological E Limited announced that the vaccine has got approval from the Drugs Controller General of India (DCGI). The company also said in its press release that it is planning to deliver over a million doses globally. 

Corbevax has been developed by Biological E Limited along with the Texas Children’s Hospital Centre for Vaccine Development and Baylor College of Medicine in Houston, Texas.

The vaccine has completed two of three-phase clinical trials with 3,000 subjects aged from 18 to 80 at 33 study sites in India. In the phase three study, it demonstrated superior immune response in comparison to Covishield Vaccine for neutralizing antibody (nAb) Geometric Mean Titers against the Ancestral-Wuhan strain and the Delta Variant.